Drug repurposing to overcome microbial resistance.

Anti-Bacterial Agents / pharmacology Anti-Infective Agents Drug Repositioning
Antibiotics Antimicrobial resistance Drug repurposing Infections Non-antibiotic drugs

Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
07 2022
Historique:
received: 21 01 2022
revised: 02 05 2022
accepted: 06 05 2022
pubmed: 14 5 2022
medline: 22 6 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Infections are a growing global threat, and the number of resistant species of microbial pathogens is alarming. However, the rapid development of cross-resistant or multidrug-resistant strains and the development of so-called 'superbugs' are in stark contrast to the number of newly launched anti-infectives on the market. In this review, I summarize the causes of antimicrobial resistance, briefly discuss different approaches to the discovery and development of new anti-infective drugs, and focus on drug repurposing strategy, which is discussed from all possible perspectives. A comprehensive overview of drugs of other indications tested for their in vitro antimicrobial activity to support existing anti-infective therapeutics is provided, including several critical remarks on this strategy of repurposing non-antibiotics to antibacterial drugs.

Identifiants

DOI: 10.1016/j.drudis.2022.05.006 PMID: 35561965
pubmed: 35561965
pii: S1359-6446(22)00193-3
doi: 10.1016/j.drudis.2022.05.006
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2028-2041

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Josef Jampilek (J)

Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, 842 15 Bratislava, Slovakia; Department of Chemical Biology, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic. Electronic address: josef.jampilek@gmail.com.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Effectiveness of bundled care in the management of cerebral hemorrhage complicated by pulmonary infection in China: A systematic review and meta-analysis.

Yamei Zhang, Xiulan Wu, Ming Lu et al.
1.00
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Drug repurposing to overcome microbial resistance.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Drug repurposing to overcome microbial resistance.
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Repositionnement des médicaments › Drug repurposing to overcome microbial resistance.